Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Naiyer Rizvi
Sloan Kettering Inst Can Research, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Gritstone Oncology
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Gritstone’s work is broadly related to research being carried out under this grant. Gritstone is developing two key classes of tumor‐specific neoantigen product candidates to treat patients with cancer. According to Dr. Rizvi, Gritstone has already developed an established algorithm to predict neoantigens and is in clinical stage at this time, while his research is aimed at defining mechanism of sensitivity and resistance to immunotherapy based on genetics to advance mechanistic understanding, not to develop a therapy. Columbia's FCOI Committee found a possibility that Dr. Rizvi’s significant financial interest in Gritstone could directly and significantly affect the design, conduct or reporting of the R35.
Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance
PROJECT NARRATIVE This proposal focuses on elucidating the genetic determinants and mechanisms underlying immune checkpoint blockade therapy efficacy and resistance. We propose to use a combination of systematic large-scale genomics, preclinical animal modeling, integrated immunogenomics profiling, and mechanism-directed immunologic analyses to establish a robust understanding of sensitivity and resistance to immune checkpoint blockade. Our studies will build the foundation for the precise and individual application on immunotherapy for cancer patients.
Filed on June 11, 2019.
Tell us what you know about Naiyer Rizvi's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Naiyer Rizvi”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Naiyer Rizvi | Sloan Kettering Inst Can Research | Conflict of Interest | Personal Genome Diagnostics | $10,000 - $19,999 |
| Naiyer Rizvi | Columbia University Health Sciences | Conflict of Interest | Personal Genome Diagnostics | $10,000 - $19,999 |
| Naiyer Rizvi | Columbia University Health Sciences | Conflict of Interest | Gritstone Oncology | $550,000 - $599,999 |
| Naiyer Rizvi | Sloan Kettering Inst Can Research | Conflict of Interest | Gritstone Oncology | >$600,000 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.